44 completed, 2 recruiting, 2 withdrawn, 1 unknown. 49 Phase 2, 7 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 49 | Completed 44, Recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 3 | 7 | Completed 6, Unknown 1 |
| Phase 1 | 6 | Completed 6 |
Follow Phobia, Social: new trials by email Literature Review of Phobia, Social trials Research Report on Phobia, Social
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NTX-1472 in Social Anxiety Disorder NTX-1472, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Recruiting | Newleos Therapeutics, Inc. | 100 | 2025-12-09 | 2026-07-09 |
| A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder ENX-102, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Engrail Therapeutics INC | 47 | 2025-09-05 | 2026-04-08 |
| Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder EMP-01, EMP-01 Placebo - Social Anxiety Disorder | Phase 2 | Completed | atai Therapeutics, Inc. | 70 | 2025-05-08 | 2026-07-31 |
| A Study of ONO-1110 in Patients With Social Anxiety Disorder ONO-1110, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 115 | 2025-01-31 | 2026-07-08 |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray - Social Anxiety Disorder | Phase 2 | Recruiting | VistaGen Therapeutics, Inc. | 60 | 2025-01-09 | 2026-02-05 |
| Social Safety Learning in the Brain Oxytocin System Oxytocin nasal spray or placebo - Social Phobia | Phase 2 | Completed | University of Washington | 121 | 2023-06-26 | 2026-06-11 |
| Cannabidiol to Reduce Anxiety Reactivity Cannabidiol, Placebo - Social Anxiety, Social Anxiety Disorder | Phase 2 | Completed | University of California, San Diego | 63 | 2023-04-19 | 2025-01-08 |
| Cannabidiol as a Treatment for Social Anxiety Disorder (R61) Cannabidiol, Placebo - Social Anxiety Disorder | Phase 2 | Completed | NYU Langone Health | 60 | 2023-01-26 | 2026-01-07 |
| Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Cannabidiol oral solution, Placebo - Social Anxiety Disorder | Phase 2 | Completed | EmpowerPharm Inc. | 239 | 2022-10-27 | 2024-11-21 |
| Social Anxiety MDMA-Assisted Therapy Investigation MDMA, Psychotherapy - Social Anxiety Disorder | Phase 2 | Completed | Jason B Luoma | 90 | 2022-04-13 | 2025-08-28 |
| A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder 225 mg BNC210, 675 mg BNC210, Placebo - Social Anxiety Disorder | Phase 2 | Completed | Bionomics Limited | 151 | 2022-02-02 | 2025-03-18 |
| Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety VQW-765, Placebo - Performance Anxiety | Phase 2 | Completed | Vanda Pharmaceuticals | 230 | 2021-02-23 | 2024-03-20 |
| CHI-902 for Treatment of Social Anxiety Disorder CHI-902, Placebo - Social Anxiety Disorder | Phase 2 | Withdrawn | Canopy Growth Corporation | 2020-01-24 | 2020-06-04 | |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy - Phobias, Claustrophobia | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 112 | 2015-08-01 | 2022-12-28 |
| A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder JNJ-42165279, Placebo - Phobic Disorders | Phase 2 | Completed | Janssen Research & Development, LLC | 150 | 2015-06-11 | 2025-04-29 |
| D-Cycloserine and Virtual Reality Exposure Therapy Seromycin, Virtual Reality Exposure Therapy, Placebo - Social Anxiety Disorder | Phase 2 | Withdrawn | Georgia State University | 2015-01-01 | 2018-04-13 | |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Bringing What Works to Youth in Corrections: A Trauma Intervention Trauma-Focused Cognitive Behavioral Therapy - Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 57 | 2012-11-01 | 2016-03-17 |
Showing 20 of 49. Sign in to see all of them.
Anxiety Disorders (14) · Generalized Anxiety Disorder (12) · Anxiety, Separation (8) · Phobic Disorders (6) · Obsessive-Compulsive Disorder (3) · Panic Disorder (3) · Psychological Well-Being (3) · Depressive Disorder, Major (2) · Mental Disorders (2) · Phobia, Specific (2) · Stress Disorders, Post-Traumatic (2) · Agoraphobia (1) · Alcoholism (1) · Asperger Syndrome (1)
Mental Disorders (47) · Phobic Disorders (43) · Anxiety Disorders (35) · Neurodevelopmental Disorders (8) · Behavior (3) · Mood Disorders (3) · Personal Satisfaction (3) · Chemically-Induced Disorders (2) · Depressive Disorder (2) · Stress Disorders, Traumatic (2) · Substance-Related Disorders (2) · Trauma and Stressor Related Disorders (2) · Alcohol-Related Disorders (1) · Autism Spectrum Disorder (1) · Child Development Disorders, Pervasive (1)
Cognitive Behavioral Therapy (5) · Paroxetine (5) · Cannabidiol (3) · Cycloserine (2) · Hypericum extract LI 160 (2) · Psychotherapy (2) · Therapeutics (2) · vestipitant (2) · Counseling (1) · Dexetimide (1) · Escitalopram (1) · GW 876008 (1) · Guanfacine (1) · Implosive Therapy (1) · JNJ-42165279 (1)
GlaxoSmithKline (4) · Duke University (2) · NYU Langone Health (2) · National Center for Complementary and Integrative Health (NCCIH) (2) · START Clinic for Mood and Anxiety Disorders (2) · Tel Aviv University (2) · University of California, Los Angeles (2) · University of California, San Diego (2) · University of South Florida (2) · University of Texas at Austin (2) · Avera Pharmaceuticals (1) · Bionomics Limited (1) · Canopy Growth Corporation (1) · Eli Lilly and Company (1) · EmpowerPharm Inc. (1)
United States (33) · Canada (6) · Norway (5) · Germany (3) · Israel (2) · South Africa (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Chile (1) · Costa Rica (1) · Denmark (1) · Finland (1) · Japan (1)
Angela Fang, PhD (1) · Asle Hoffart, Dr Psychol (1) · Carrie Masia, Ph.D. (1) · Charles Taylor, PhD (1) · Denise A Chavira, PhD (1) · Einar Heiervang, MD (1) · Eric A Storch, Ph.D. (1) · Esther Blessing, MD (1) · Finn-Magnus Borge, Cand Psychol (1) · Frances R Levin, MD (1) · Gro Janne H Wergeland, MD PhD (1) · Jason B Luoma, Ph.D. (1)
PMID 16540816, PMID 20018493, PMID 22233247, PMID 22647314, PMID 22659077, PMID 23108976, PMID 23257654, PMID 23357440, PMID 24666527, PMID 24700254, PMID 24727078, PMID 25461793, PMID 25637909, PMID 26583954, PMID 26647901, PMID 27002215, PMID 27435286, PMID 28165762, PMID 28559206, PMID 29195188, PMID 29792485, PMID 30082367, PMID 30138014, PMID 33070154, PMID 34284836, PMID 37520237, PMID 39954310
2014 (1), R01MH081881 (1), R34MH090149 (1), R34MH095210 (1)